Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women
Gilead Sciences, Inc. (NASDAQ: GILD) today announced 48-week results from a Phase 2/3 study (Study GS-US-380-1474) evaluating the efficacy and safety of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF), a once-daily single tablet regimen, in virologically suppressed adolescents and children at least 6 years of age who are living with HIV. Through Week 48, Biktarvy maintained high rates of virologic suppression with a low incidence of study drug-related adverse events and no treatment-emergent resistance. The data were presented at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
“These findings indicate that Biktarvy, an oral single-tablet regimen that can be taken with or without food, has the potential to be an effective and well-tolerated treatment option for some children and adolescents living with HIV,” said Aditya H. Gaur, MD, Clinical Director, Department of Infectious Diseases at St. Jude Children’s Research Hospital and lead study investigator. “Importantly, Biktarvy was not associated with any cases of treatment-emergent resistance through 48 weeks of treatment, a result observed consistently to date across the Biktarvy clinical research programs and a significant consideration for children and adolescents who are facing the prospect of long-term treatment.”
Biktarvy is indicated in the U.S. as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history. Biktarvy is also indicated to replace the current antiretroviral regimen in those adults who are virologically suppressed on a stable antiretroviral regimen for at least three months. Virologically suppressed adults must have no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy. Biktarvy carries a Boxed Warning in its U.S. product label regarding the risk of post-treatment acute exacerbation of hepatitis B. See below for Important Safety Information.
Studies of Biktarvy and other TAF-based regimens in specific populations presented at the conference included:
Oral 2571: Biktarvy Single-Tablet Regimen in Adolescents & Children: Week 48 results
The 48-week, single-arm, open-label trial enrolled 50 virologically suppressed adolescents aged 12 to <18 years old and weighing ≥35 kg and 50 virologically suppressed children aged 6 to <12 years old and weighing ≥25 kg. All study participants had an undetectable viral load (HIV-1 RNA <50 c/mL) for at least six months before screening and CD4 cell counts of ≥200 cells/µL. Patients received a full adult strength Biktarvy tablet once daily.
At Week 48, 98 percent (n=74/75) of patients maintained an undetectable viral load, as defined by the US FDA snapshot algorithm. The remaining one patient had a reported HIV-1 RNA level of 85 c/ml at Week 48, but re-suppressed and achieved an undetectable viral load within two weeks. No participant in the study developed treatment-emergent resistance. Abdominal discomfort (grade 1) was the only study drug-related adverse event (AE) reported in more than one patient (2 percent; n=2).
In addition to efficacy and safety, the study evaluated the impact of the Biktarvy tablet on adherence in this patient population. All participants reported that the size and shape of the Biktarvy tablet was acceptable and the taste was palatable. The median percent adherence to Biktarvy, measured by pill count, was 99 percent.
The efficacy and safety profile of Biktarvy in adolescents and children has not been established; its use in these populations is investigational.
Poster 2586: 96 Week Efficacy and Safety of Biktarvy in Treatment-Naïve Adults and Adults ≥50 Years
A post-hoc analysis of data from two randomized, double-blind, Phase 3 studies (Studies 1489 and 1490) evaluated Biktarvy in treatment-naïve adults aged 50 and older (n=96/634), at Week 96. Treatment with Biktarvy resulted in high rates of virologic suppression regardless of age. Biktarvy was well tolerated in both the overall and the 50 year and older patient subgroups. There was no clinically significant impact on bone mineral density and renal laboratory parameters in patients aged 50 and older, a population at higher risk for comorbidities.
Poster 0519: Tenofovir Alafenamide vs Tenofovir DF in Women: Pooled Analysis of 7 Clinical Trials
A pooled analysis of data from 779 women in seven randomized, double-blind clinical trials (two in treatment-naïve adults and five in virologically suppressed adults) evaluated the efficacy and safety of TAF-based versus TDF-based regimens for antiretroviral treatment initiation or switch through Week 96. All participants who initiated or switched to TAF-based regimens, including Biktarvy, were compared with those who initiated or continued TDF-based regimens. Women who initiated or switched to TAF-based regimens had significantly improved bone and renal safety parameters compared to those who initiated or continued TDF-based regimens, with similar rates of virologic suppression. Discontinuations due to AEs were low in both groups.
“Gilead’s ongoing investment in HIV treatment research and development is focused on bringing the latest innovations and the potential for successful, long-term treatment to as many people living with HIV as possible,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “Results from these studies in specific populations presented at CROI demonstrate that Biktarvy has the potential to be appropriate for use in a broad range of patients who are new to therapy or switching therapies, including young people and aging adults, as well as women who have been traditionally underrepresented in HIV clinical trials.”
Biktarvy does not cure HIV infection or AIDS.
IMPORTANT U.S. SAFETY INFORMATION AND INDICATION FOR BIKTARVY
BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
- Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of Biktarvy. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue Biktarvy. If appropriate, anti-hepatitis B therapy may be warranted.
- Coadministration: Do not use Biktarvy with dofetilide or rifampin.
Warnings and precautions
- Drug interactions: See Contraindications and Drug Interactions sections. Consider the potential for drug interactions prior to and during Biktarvy therapy and monitor for adverse reactions.
- Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.
New onset or worsening renal impairment: Cases of acute
renal failure and Fanconi syndrome have been reported with the use of
tenofovir prodrugs. In clinical trials of Biktarvy, there have been no
cases of Fanconi syndrome or proximal renal tubulopathy (PRT). Do not
initiate Biktarvy in patients with estimated creatinine clearance
(CrCl) <30 mL/min. Patients with impaired renal function and/or taking
nephrotoxic agents (including NSAIDs) are at increased risk of
renal-related adverse reactions. Discontinue Biktarvy in patients who
develop clinically significant decreases in renal function or evidence
of Fanconi syndrome.
Renal monitoring: Prior to or when initiating Biktarvy and during therapy, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, also assess serum phosphorus.
- Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue Biktarvy if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.
- Most common adverse reactions (incidence ≥5%; all grades) in clinical studies through week 96 were diarrhea (6%), nausea (6%), and headache (5%).
- Prescribing information: Consult the full prescribing information for Biktarvy for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments.
- Enzymes/transporters: Drugs that induce P-gp or induce both CYP3A and UGT1A1 can substantially decrease the concentration of components of Biktarvy. Drugs that inhibit P-gp, BCRP, or inhibit both CYP3A and UGT1A1 may significantly increase the concentrations of components of Biktarvy. Biktarvy can increase the concentration of drugs that are substrates of OCT2 or MATE1.
- Drugs affecting renal function: Coadministration of Biktarvy with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC and tenofovir and the risk of adverse reactions.
Pregnancy and lactation
- Pregnancy: There is insufficient human data on the use of Biktarvy during pregnancy. An Antiretroviral Pregnancy Registry (APR) has been established. Available data from the APR for FTC shows no difference in the rates of birth defects compared with a US reference population.
- Lactation: Women infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission.
Dosage and administration
- Dosage: 1 tablet taken once daily with or without food.
- Renal impairment: Not recommended in patients with CrCl <30 mL/min.
- Hepatic impairment: Not recommended in patients with severe hepatic impairment.
- Prior to or when initiating: Test patients for HBV infection.
- Prior to or when initiating, and during treatment: As clinically appropriate, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, assess serum phosphorus.
Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen for ≥3 months with no history of treatment failure and no known resistance to any component of Biktarvy.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it’s estimated that more than 11.5 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that Biktarvy may not be approved for the treatment of HIV-1 infection in adolescents and children and the possibility of unfavorable results from additional clinical trials involving Biktarvy. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
U.S. full Prescribing Information for Biktarvy, including BOXED WARNING, is available at www.gilead.com .
Biktarvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Sung Lee, Investors
Ryan McKeel, Media
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Fiorano Partners with Konsentus to Lower Costs and Risks Associated with PSD2 Compliance25.3.2019 12:00:00 EET | Tiedote
Fiorano Software, a leading Enterprise Middleware, Integration and API Management specialist, announced today that it has added Third Party Provider (TPP) Identity & Regulatory checking services from Konsentus, a UK based Regtech company providing live SaaS-based APIs to check TPP identity & regulatory status, to its ready-to-deploy PSD2 platform to provide enhanced support to Financial Institutions (FIs) working towards PSD2 compliance. Biju Suresh Babu, Global Open Banking lead, Fiorano comments, "Having recently launched the Fiorano PSD2 Accelerator , which is designed to provide FIs (ASPSPs in PSD2 terms) with the technology required to meet PSD2 open banking regulatory obligations as a pre-integrated bundle, we are delighted to be able to offer our customers a unique solution to solve their specific challenges around TPP identity and regulatory checking.” Whilst the first major deadline passed on 14th March, whereby FIs had to make their ASPSP interfaces available for external tes
TSG Consumer Partners Opens London Office25.3.2019 11:30:00 EET | Tiedote
TSG Consumer Partners (“TSG”), a leading private equity firm focused exclusively on the branded consumer sector, today announced that it has opened an office in London, its first office outside the U.S. TSG’s presence in London deepens its commitment to the European market and enhances the firm’s ability to identify and execute on compelling investment opportunities in the region. TSG’s foothold in Europe comes following a series of investments in leading European companies such as Revolution Beauty – which was recently named the third fastest growing private company by the Sunday Times Fast Track 100 – BrewDog, Canyon Bicycles, Bergfreunde.de, as well as ZOEVA and HUDA Beauty, both of which opened offices in London last year. Beth Pickens, former Managing Director and head of European consumer banking at William Blair, has joined TSG as a Principal based in London. Colin Welch, Partner and Managing Director at TSG, is responsible for guiding the new office located in Mayfair. “Europe
Continuing Its Collaboration with ITER Organization, CNIM is Designing and Manufacturing High-Precision Handling Equipment to Assemble Components of the Future Fusion Reactor25.3.2019 10:30:00 EET | Tiedote
CNIM has announced the launch of the third phase of the Purpose Built Tools (PBT) framework agreement signed with ITER Organization in December 2016. This agreement covers the engineering, manufacturing and installation of special tools for the installation of ITER Tokamak. It entails the design and manufacture of extremely large lifting systems to handle parts weighing up to 4 metric tons. These structures, comprising two 8-level towers (18 meters tall) weighing some 40 metric tons, will equip the Sector Sub-Assembly Tools (SSAT). The SSATs will be used to assemble each sector of the vacuum chamber of the fusion reactor before its transfer to the reactor building where they will all be assembled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005051/en/ 1250 tons cryostat handling system (c) CNIM Under the same contract, CNIM has also been entrusted with defining nine types of special, strategic tools for ITER. These
ITER Organization Chooses Bertin Technologies to Design a Density Interferometer Polarimeter25.3.2019 10:30:00 EET | Tiedote
Bertin Technologies , a subsidiary of CNIM Group , has received a contract from ITER Organization for the preliminary design of the “Density Interferometer Polarimeter” (DIP), a complex optical diagnostic system that measures plasma density during nuclear fusion reactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005118/en/ “Density Interferometer Polarimeter” (DIP) Copyright Bertin Technologies This is a key component of the tokamak reactor’s future diagnostic instruments. The purpose of the DIP will be to help control plasma by measuring the density of the electrons in order to ensure its stability and obtain an optimal energy yield. Optical instrumentation design and manufacturing, such as the DIP technology, are key areas of excellence at Bertin Technologies, the French leader of industrial innovation for this field. Collaborating with the ITER program since 2009, through contracts with the ITER Organization
Panasonic’s Next-generation HD-PLC®*1, BPL Communication Technology Adopted as IEEE 1901a Standard25.3.2019 05:14:00 EET | Tiedote
On March 25, 2019, Panasonic Corporation announced that the IEEE Standards Association has approved the company’s next-generation broadband over powerline (BPL) communication technology for Internet of Things (IoT) as the IEEE 1901a Standard on March 21, 2019 at the Standards Board meeting in Munich, Germany. The company proposed the technology to the IEEE Standardization 1901a Working Group*2 in June 2018. This standard flexibly meets various demands for IoT-related services. IEEE 1901a, BPL communication standard for IoT enables to control frequency bands according to usage. It allows scalable communications with features to extend communication distances and to select speeds. The flexible features defined in this standard enable to address the diverse communication needs of IoT-related services. It implements the following new functions based on the Panasonic original HD-PLC ® Wavelet OFDM technology (standard mode), already adopted in the IEEE 1901-2010 standard. The standard mode
Earth Networks Launches Aviation Early Warning System for the Agency for the Safety of Air Navigation in Africa and Madagascar (ASECNA)25.3.2019 02:00:00 EET | Tiedote
Earth Networks today announced it has completed a new aviation early weather warning system for The Agency for the Safety of Air Navigation in Africa and Madagascar (ASECNA). The announcement was made at the 6th annual InterMET Asia conference in Singapore. Designed for air traffic management and airport operations professionals to issue alerts on severe weather and lightning threats that have the potential to affect air and land operations including ground crews, fueling, and aircraft, the newly operational global aviation early warning system includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network, featuring over 1,700 sensors in more than 100 countries On-the-ground weather monitoring via the Earth Networks Weather Network Sferic Maps, a web-based severe weather monitoring and alerting platform Severe weather data and visualization tools such as Dangerous Thunderstorm Alerts and PulseRad, a lightning-derived radar alternative Short-range point f
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme